Dr. 复·小课堂｜乘风破浪的CAR-T细胞

数据来源及参考资料：

[1] 国家癌症中心，2019.1.

[2] China Globocan 2018.

[3] 李小秋等. 诊断学理论与实践 2012;11(2): 111-5. Crump M, et al. Blood. 2017; 130(16):1800-1808.  

[4] DLBCL=弥漫大B细胞淋巴瘤

一线治疗数据来源：Coiffier B, Sarkozy C. 2016(1):366-378.

Sehn LH, Gascoyne RD. Blood. 2015;125(1):22-32

二线及后线治疗数据来源：Crump M, et al. Blood. 2017;130(16):1800-1808

[5] Sarkizova S, Hacohen N. Nature 2017; 551(7681):444-446.

[6] Sharpe M, Mount N. Dis Model Mech 2015; 8(4):337-50.

https://scienceblog.cancerresearchuk.org/2016/01/19/engineering-a-cancer-fighting-immune-super-soldier/

https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/immunotherapy/types/CAR-T-cell-therapy

[7] Britten O,et al.Cells.2019 Oct 29;8(11).pii:E1341.

[8] 姚超, 钱程. 中国肿瘤生物治疗杂志 2017;24(1):6-11.  刘茜等. 生命的化学 2016; 26(5):661-665.

https://about-cancer.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/immunotherapy/types/CAR-T-cell-therapy?_ga=2.118270604.460738944.1587691430-744162650.1587691430 

[9] Topp M, et al. 2019 ASH abstract 243.

http://www.biodiscover.com/news/research/725695.html

[10] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)B-cell lymphomas. Version 1.2020.

[11] 中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南2020